| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a7f82940e47ba7a1188f8e2ffca55e0f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2299-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H21-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D209-20 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D209-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-63
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N1-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H21-04 |
| filingDate |
2009-11-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e23b59dad280d280545fd4903323814e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c2d59c73327105f5375b41f5e00884f1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_68391df1dbafe661b5ef7510b6f560d8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_becb8e9edef9f8acfeab81025ef758ff
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_95a788709cfd20cf69a8f6bfbc4e1a3b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d7a7fcdb7411fd45c8a373f75fd5378b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c5bfe533fb7a22ed8b8aeb0121c772b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f99658d942f14980e5fb27f9e1d43657
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cd1159e60149158b4a141933d863cbe8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_302fd16aa3fb89358f2b8eeb40ef49e0 |
| publicationDate |
2010-06-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2010136620-A1 |
| titleOfInvention |
Soluble, stable form of hdm2, crystalline forms thereof and methods of use thereof |
| abstract |
The present invention discloses modified Hdm2 proteins that are soluble. In addition, the present invention discloses nucleic acids that encode the modified Hdm2 proteins of the present invention. The invention also provides crystals of modified Hdm2 proteins that are suitable for X-ray crystallization analysis. The present invention also discloses methods of using the modified Hdm2 proteins and crystals thereof to identify, select and/or design compounds that may be used as anticancer agents. The present invention further discloses compounds that bind to modified Hdm2 proteins in protein-ligand complexes. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2017182137-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10293035-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11160853-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11185578-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010139620-A1 |
| priorityDate |
2003-04-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |